These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. Zheng MM; Tu HY; Yang JJ; Zhang XC; Zhou Q; Xu CR; Jiang BY; Yang XN; Yang XR; Deng JY; Yang MY; Xu BF; Chen XM; Li YS; Wu YL Eur J Cancer; 2021 Jun; 150():23-30. PubMed ID: 33882375 [TBL] [Abstract][Full Text] [Related]
25. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression. Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391 [TBL] [Abstract][Full Text] [Related]
28. FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. Dimitriou F; Lo SN; Tan AC; Emmett L; Kapoor R; Carlino MS; Long GV; Menzies AM Ann Oncol; 2022 Jan; 33(1):99-106. PubMed ID: 34687894 [TBL] [Abstract][Full Text] [Related]
29. FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer. Seban RD; Assie JB; Giroux-Leprieur E; Massiani MA; Soussan M; Bonardel G; Chouaid C; Playe M; Goldfarb L; Duchemann B; Girard N; Champion L Ann Nucl Med; 2020 Dec; 34(12):968-974. PubMed ID: 33070295 [TBL] [Abstract][Full Text] [Related]
30. Hyperprogressive Disease in Patients with Non-Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of Castello A; Rossi S; Mazziotti E; Toschi L; Lopci E J Nucl Med; 2020 Jun; 61(6):821-826. PubMed ID: 31862803 [TBL] [Abstract][Full Text] [Related]
31. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589 [TBL] [Abstract][Full Text] [Related]
32. Effect of PET/CT standardized uptake values on complete response to treatment before definitive chemoradiotherapy in stage III non-small cell lung cancer. Ercelep O; Alan O; Sahin D; Telli TA; Salva H; Tuylu TB; Babacan NA; Kaya S; Dane F; Ones T; Alkis H; Adli M; Yumuk F Clin Transl Oncol; 2019 Apr; 21(4):499-504. PubMed ID: 30229391 [TBL] [Abstract][Full Text] [Related]
33. [Positron emission tomography with 18F-FDG and cancer response to chemotherapy]. van Ruychevelt V; Garcia C; Meert AP; Berghmans T; Paesmans M; Flamen P; Sculier JP Rev Mal Respir; 2011 May; 28(5):618-25. PubMed ID: 21645832 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: A two-center retrospective study. Yao J; Wang Z; Sheng J; Wang H; You L; Zhu X; Pan H; Han W Int Immunopharmacol; 2020 Dec; 89(Pt A):107033. PubMed ID: 33039958 [TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of 2-[(18)F] Fluoro-2-deoxy-D-glucose Positron Emission Tomography-Computed Tomography Scan Carried out During and After Radiation Therapy for Head and Neck Cancer Using Visual Therapy Response Interpretation Criteria. Min M; Lin P; Lee M; Ho Shon I; Lin M; Forstner D; Tieu MT; Chicco A; Bray V; Fowler A Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):393-401. PubMed ID: 26782837 [TBL] [Abstract][Full Text] [Related]
36. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Alessandrino F; Sahu S; Nishino M; Adeni AE; Tirumani SH; Shinagare AB; Awad MM Abdom Radiol (NY); 2019 May; 44(5):1917-1927. PubMed ID: 30790009 [TBL] [Abstract][Full Text] [Related]
37. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Hosoya K; Fujimoto D; Morimoto T; Kumagai T; Tamiya A; Taniguchi Y; Yokoyama T; Ishida T; Hirano K; Matsumoto H; Kominami R; Tomii K; Suzuki H; Hirashima T; Uchida J; Morita M; Kanazu M; Sawa N; Makio T; Hara S; Tamiya M Clin Lung Cancer; 2020 Jul; 21(4):e315-e328. PubMed ID: 32113737 [TBL] [Abstract][Full Text] [Related]
38. Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy. Moon SH; Cho SH; Park LC; Ji JH; Sun JM; Ahn JS; Park K; Choi JY; Ahn MJ Eur J Nucl Med Mol Imaging; 2013 Jul; 40(7):1005-13. PubMed ID: 23595109 [TBL] [Abstract][Full Text] [Related]
39. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. Seban RD; Mezquita L; Berenbaum A; Dercle L; Botticella A; Le Pechoux C; Caramella C; Deutsch E; Grimaldi S; Adam J; Ammari S; Planchard D; Leboulleux S; Besse B Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1147-1157. PubMed ID: 31754795 [TBL] [Abstract][Full Text] [Related]
40. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy. Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]